These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 31935015)

  • 21. Expensive cancer drugs with modest benefit ignite debate over solutions.
    Sinha G
    J Natl Cancer Inst; 2008 Oct; 100(19):1347-9. PubMed ID: 18812543
    [No Abstract]   [Full Text] [Related]  

  • 22. Accelerated approvals hit the target in precision oncology.
    Subbiah V; Wirth LJ; Kurzrock R; Pazdur R; Beaver JA; Singh H; Mehta GU
    Nat Med; 2022 Oct; 28(10):1976-1979. PubMed ID: 36192554
    [No Abstract]   [Full Text] [Related]  

  • 23. The economic evaluation of personalised oncology medicines: ethical challenges.
    Lewis JR; Lipworth WL; Kerridge IH; Day RO
    Med J Aust; 2013 Oct; 199(7):471-3. PubMed ID: 24099207
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Approvals in 2016: questioning the clinical benefit of anticancer therapies.
    Booth CM; Del Paggio JC
    Nat Rev Clin Oncol; 2017 Feb; 14(3):135-136. PubMed ID: 28218259
    [No Abstract]   [Full Text] [Related]  

  • 25. The role of companion diagnostic testing in payer decision making.
    Conway J
    Am J Manag Care; 2013; 19(1 Spec No):cover, SP44-5. PubMed ID: 23461473
    [No Abstract]   [Full Text] [Related]  

  • 26. FDA Approval of Tisagenlecleucel: Promise and Complexities of a $475 000 Cancer Drug.
    Bach PB; Giralt SA; Saltz LB
    JAMA; 2017 Nov; 318(19):1861-1862. PubMed ID: 28975266
    [No Abstract]   [Full Text] [Related]  

  • 27. Pharmacoeconomic analyses make way into oncology.
    Amber D
    J Natl Cancer Inst; 2000 Aug; 92(15):1204-5. PubMed ID: 10922402
    [No Abstract]   [Full Text] [Related]  

  • 28. Making precision oncology the standard of care.
    The Lancet Oncology
    Lancet Oncol; 2017 Jul; 18(7):835. PubMed ID: 28677559
    [No Abstract]   [Full Text] [Related]  

  • 29. Drug-Drug Interactions With Oral Antineoplastic Agents.
    Parsad S; Ratain MJ
    JAMA Oncol; 2017 Jun; 3(6):736-738. PubMed ID: 27737450
    [No Abstract]   [Full Text] [Related]  

  • 30. Oncology drugs enter the US market faster than in Europe but cost more.
    Mitka M
    JAMA; 2012 Aug; 308(6):555. PubMed ID: 22871850
    [No Abstract]   [Full Text] [Related]  

  • 31. A Time-Trend Economic Analysis of Cancer Drug Trials.
    Cressman S; Browman GP; Hoch JS; Kovacic L; Peacock SJ
    Oncologist; 2015 Jul; 20(7):729-36. PubMed ID: 26032135
    [TBL] [Abstract][Full Text] [Related]  

  • 32. US Cancer Care System Ill-Equipped to Deliver New Advances to Patients.
    Rappaport M
    J Oncol Pract; 2016 May; 12(5):397. PubMed ID: 27170686
    [No Abstract]   [Full Text] [Related]  

  • 33. Perspectives on Cost and Value in Cancer Care.
    Saltz LB
    JAMA Oncol; 2016 Jan; 2(1):19-21. PubMed ID: 26501848
    [No Abstract]   [Full Text] [Related]  

  • 34. Trastuzumab emtansine and cost-based decision making.
    The Lancet
    Lancet; 2017 Jan; 389(10064):2. PubMed ID: 28091366
    [No Abstract]   [Full Text] [Related]  

  • 35. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs.
    Berry SR; Bell CM; Ubel PA; Evans WK; Nadler E; Strevel EL; Neumann PJ
    J Clin Oncol; 2010 Sep; 28(27):4149-53. PubMed ID: 20697077
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expensive cancer therapies: unintended effects.
    Delude CM
    J Natl Cancer Inst; 2015 Jan; 107(1):497. PubMed ID: 25564602
    [No Abstract]   [Full Text] [Related]  

  • 37. Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA.
    Bennett CL; Sartor OA; Armitage JO; Kantarjian H
    Lancet Oncol; 2017 Jan; 18(1):22-23. PubMed ID: 28049571
    [No Abstract]   [Full Text] [Related]  

  • 38. Evolving Landscape of US Food and Drug Administration Drug Approval in the Era of Precision Oncology: Finding the Right Balance Between Access and Safety.
    Kuderer NM; Lyman GH
    J Clin Oncol; 2018 Jun; 36(18):1773-1776. PubMed ID: 29742010
    [No Abstract]   [Full Text] [Related]  

  • 39. Examining Trends in Cost and Clinical Benefit of Novel Anticancer Drugs Over Time.
    Saluja R; Arciero VS; Cheng S; McDonald E; Wong WWL; Cheung MC; Chan KKW
    J Oncol Pract; 2018 May; 14(5):e280-e294. PubMed ID: 29601250
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemotherapy treatment options and policies.
    Breshears Wheeler J; Hanson K
    NCSL Legisbrief; 2012 May; 20(19):1-2. PubMed ID: 22666895
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.